

ESMO 2022 Industry Satellite Symposium

ER+ / HER2- BREAST CANCER:

What's next for patients & providers?



DATE: MONDAY, 12 SEPTEMBER 2022
TIME: 18:30-20:00 CEST

**7.3.O - ORLÉANS AUDITORIUM, HALL 7, LEVEL 7.3,
PARIS EXPO PORTE DE VERSAILLES, PARIS, FRANCE**



François-Clément Bidard



Nadia Harbeck



Arlene Chan

01

Welcome and Introduction

Prof. François-Clément Bidard, MD, PhD
Institut Curie, Paris, France

18:30 – 18:35 CEST

02

Opportunity to Improve on the Standard of Care in Adjuvant ER+/HER2- Breast Cancer

Prof. Nadia Harbeck, MD, PhD
Ludwig-Maximilians University Hospital, Munich, Germany

18:35 – 19:00 CEST

03

Current Management Considerations in ER+/HER2- Metastatic Breast Cancer

Prof. François-Clément Bidard, MD, PhD
Institut Curie, Paris, France

19:00 – 19:20 CEST

04

Oral SERDs & Novel ETs in ER+/HER2- Metastatic Breast Cancer

Prof. Arlene Chan, MBBS, FRACP, MMed
Curtin University, Perth, Australia

19:20 – 19:45 CEST

05

Live Q&A with the Panel

Chair & Speakers

19:45 – 20:00 CEST

sanofi

MAT-GLB-2202685 v1.0 Approval Date: 06/2022